17,261 trials
Breast Cancer
Primary: Number of Participants With Disease Control Rate at 9 Months — 35 Participants
Colitis, Ulcerative
Primary: Proportion of Participants With Endoscopic Improvement (MCS mESS ≤1) at Week 12 — 0.375; 0.143 Proportion of participants
Alcohol Use Disorder
Primary: Negative Affect — 2.91; 2.47 units — p=.62
Leukemia · Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Maximum Tolerated Dose (MTD) of Nivolumab — NA; 3 mg/kg
Prader-Willi Syndrome · Hyperphagia
Primary: Hyperphagia Questionnaire (HQ)- Total Score — 27.91; 30.58; 27.4; 23.33 score on a scale — p=0.059
Chronic Liver Disease · HepatoCellular Carcinoma
Primary: Diagnostic Value Evaluation for HCC — 62; 80; 86; 100 percent
Postoperative Fistula
Primary: Change in Average 3-day Fistula Percent Volume — 76.33; 441.67 Percent change in fistula volume
Acute Myeloid Leukemia
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Peg-IFN-α — 180 mcg
COVID-19
Primary: Change From Baseline in the Number of Participants With Seroconversion to SARS-CoV-2 at 1 Month — 4; 2 Participants
Postoperative Ileus
Primary: Time to First Bowel Movement — 61.8; 50.7 hours — p=0.81
Benign Prostatic Hyperplasia · Lower Urinary Track Symptoms
Primary: American Urologic Association Symptom Score (AUASS) — 18.66; 14.16 score on a scale
Melanoma
Primary: Intracranial Clinical Benefit Rate (CBR) — 57.4; 16.7 Percentage of Participants
Opioid Sensitivity · Individual Difference · Abuse Opioids
Primary: Self-report Visual Analog Ratings of HIGH — 7.2; 6.6; 4.5; 5.6 score on a scale — p=0.567
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Primary: 2-year Overall Survival (Phase II) — 66.5; 55.5 percentage of participants
Subarachnoid Hemorrhage, Aneurysmal
Primary: Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) — 2; 1 Participants